November 2025. Reviews pharmacy benefit manager approaches to oncology medication distribution, management, and the resulting contracting landscape across medication types.
Managed Oncology
2025 Research
November 2025. Examines Medicare Advantage plans' approaches to oncology medication management, the resulting contracting environment, and MA plans' evaluations of pharmaceutical manufacturers active in oncology.
August 2025. Reviews commercial health plan approaches to oncology management and examines the resulting market access landscape across cancer types.
July 2025. Examines the contracting environment and commercial health plan executive evaluations of 30+ pharmaceutical manufacturers active in oncology.
March 2025. Provides an overview of the community oncology practice segment, including PDL and clinical pathway development by cancer type, oncology pharmacy and dispensing services, manufacturer engagement ratings, and overall partner of choice nominations.
March 2025. Reviews Cancer Centers' strategic imperatives, market trends, pharmacy and dispensing services, and perceptions of manufacturer account engagement and support personnel.
-
Pharmacy benefit managers (PBMs) are tightening utilization management and formulary strategies to more effectively manage oncology spend in 2026 and beyond. HIRC's report, Pharmacy Benefit Managers...
-
The evolving policy landscape, driven by the Inflation Reduction Act and emerging Maximum Fair Price regulations, is transforming how Medicare Advantage plans approach contracting and management of...
-
Commercial MCOs are ramping up bold, proactive strategies to control oncology drug costs and utilization, driven by the surge of groundbreaking therapies entering the market. HIRC's report,...
-
Payer expectations for manufacturer engagement in oncology are evolving as the contracting environment grows increasingly competitive. HIRC's report, Commercial Health Plans: Manufacturer Account...
-
In response to declining reimbursement and other market changes, community oncology practices (COPs) are strategically focusing on enhancing their practices' competitiveness and strengthening their...
Managed Oncology
Research Overview
As the oncology drug pipeline continues to deliver innovative therapies, payers and other health care stakeholders continue to seek strategies that ensure appropriate utilization. HIRC's Managed Oncology Service examines issues in oncology medication management and distribution to assist pharmaceutical firms in developing and maintaining successful market access strategies.
HIRC utilizes a triangulated research design, combining primary survey data, interview insights, and in-depth secondary research, resulting in a deep understanding of issues related to oncology medication market access.
Cancer Therapy Categories analyzed:
- Oral Conventional Chemotherapies
- IV Conventional Chemotherapies
- Oncology Biosimilars
- Oncology Brand Originators
- Oral Targeted Therapies
- IV Targeted Therapies
- Immune Checkpoint Inhibitors
- CAR-T Cell Therapies
- Bispecific Antibodies
- 20+ Targeted Cancer types, download Service Summary for complete listing
For more information or to subscribe, contact Raymond Co via email or at (408) 884-8560
Comprehensive Approach to Managed Markets Access
The service monitors managed care strategic imperatives and trends related to oncology medication cost and utilization management across Commercial, PBM, and Medicare Advantage payer segments. Trends in oncology distribution and management are also tracked in two key oncology provider market segments. The service also examines manufacturer engagement across and contracting trends.
- Academic and Health System-based Cancer Centers
- Community Oncology Practices
- Commercial Health Plans
- Pharmacy Benefit Managers
- Medicare Advantage Plans
Bringing Value to Subscribers
HIRC's data and insights enable subscribers to understand and track market dynamics and trends critical to optimal product positioning as the managed oncology market evolves.
Through detailed analyses, key implications, and strategic recommendations from experienced HIRC researchers, subscribers to the Managed Oncology Service are able to identify potential opportunities for partnerships and evaluate account management strategies to effectively support the oncology-specific needs of managed care.
